(Reuters) -Genetic test maker Invitae is preparing to file for bankruptcy within weeks, the Wall Street Journal reported onMonday, according to people familiar with the matter. Shares of the San ...
– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Invitae (NVTA ...
Invitae’s business operations are heading to a new home. Under a bankruptcy auction, Labcorp was selected as the winning bidder for the firm’s genetic testing services, digital health solutions, and ...
Invitae's business has been growing rapidly and there's still more growth on the horizon. The beaten-up stock is a risky buy given its significant losses and persistent cash burn. There's significant ...
Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...
Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min More than 4 million people have ...
A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 ...
Updates with details from statement in paragraphs 2 and 5, adds details from bankruptcy filing in paragraphs 3-4, background in paragraph 6 To ensure its business operates as usual, Invitae has ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will host an investor conference call on Wednesday, October 7 at 4:30 p.m.
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...